Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Daiichi Sankyo Settles Evoxac Suit Against Apotex

Daiichi Sankyo Co. said generic-drug maker Apotex Inc. agreed not to sell a lower-cost version of the dry-mouth treatment Evoxac in the U.S. until 2012 under the terms of a patent-infringement suit settlement.

Apotex, Canada’s biggest drugmaker, can enter the market in the fourth quarter of 2012 under a license from Daiichi Sankyo, the Japanese drug manufacturer said in a statement. The agreement ends a suit in which Daiichi Sankyo sought to block the copy until a patent on the drug expires in July 2013.

Evoxac, approved by U.S. regulators in 2000, is used to treat dry mouth in patients with Sjogren’s Syndrome. The syndrome, which affects 4 million people in the U.S., is an autoimmune disease in which white blood cells attack moisture-producing glands, according to the Sjogren’s Syndrome Foundation website.

The case is Daiichi Sankyo Co. v. Apotex Inc., 09CV470, U.S. District Court, District of Delaware (Wilmington).

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.